skip to Main Content

FDA Approves Olaparib for Frontline Maintenance in Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
The FDA has approved the PARP inhibitor olaparib (Lynparza) for the maintenance treatment of adult patients with germline BRCA-mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen.

The approval is based on data from the phase III POLO trial, which showed a progression-free survival (PFS) benefit with olaparib compared with placebo in this setting. Read more . . . 


Back To Top